Frequency of brain metastases from prostate cancer: an 18-year single-institution experience.

Published on Jan 1, 2013in Journal of Neuro-oncology3.267
· DOI :10.1007/S11060-012-0994-1
Orazio Caffo36
Estimated H-index: 36
,
Antonello Veccia14
Estimated H-index: 14
+ 4 AuthorsEnzo Galligioni25
Estimated H-index: 25
Sources
Abstract
It has recently been reported that the incidence of brain metastases (BMs) from prostate cancer (PC) has increased in comparison with historical series. The aim of this study was to compare the incidence of BMs in the pre- and post-docetaxel era in a single institution in which all oncological patients are referred to one Radiotherapy and one Medical Oncology Department. We searched the electronic databases of these departments for all males with BMs entered from 1994 to 2011. The year of the introduction of docetaxel into clinical practice (2002) divided the observation period into two 9-year periods: period 1 (P1) from 1994 until 2002 (P1), and period 2 (P2) after 2002. The number of patients with BMs was constant: 241 patients in P1 and 249 in P2. The greatest changes in frequency between P1 and P2 involved colorectal cancer (+75.9 %), renal cancer (+141.9 %), and PC (+238.7 %). The total number of patients with BMs from PC was nine: two in P1 (0.8 %) and seven in P2 (2.8 %). All but two of these patients developed BMs after becoming castration-resistant. Median BM-free survival was 36 months, whereas median BM survival was 8 weeks. As the appearance of BMs in the natural history of PC is usually related to the late phase of the disease, and mortality due to PC remained constant, it seems that there really has been an increase in the frequency of BMs from PC that may reflect a gain in survival.
📖 Papers frequently viewed together
14 Citations
209 Citations
References28
Newest
#1Jean-Pierre GérardH-Index: 46
#2David AzriaH-Index: 56
Last. Thierry ConroyH-Index: 60
view all 21 authors...
Purpose The ACCORD 12 trial investigated the value of two different preoperative chemoradiotherapy (CT-RT) regimens in T3-4 Nx M0 resectable rectal cancer. Clinical results are reported after follow-up of 3 years.
269 CitationsSource
#1Howard I. Scher (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 6
#2Karim FizaziH-Index: 103
Last. B ChH-Index: 1
view all 21 authors...
Background Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor–signaling pathway, the major driver of prostate-cancer growth. We aimed to evaluate whether enzalutamide prolongs survival in men with castration-resistant prostate cancer after chemotherapy. Methods In our phase 3, double-blind, placebo-controlled trial, we stratified 1199 men with castration-resistant prostate cancer after chemotherapy according to the Eastern Cooperative Oncology Group performanc...
2,793 CitationsSource
#1Orazio CaffoH-Index: 36
#2Angela GernoneH-Index: 10
Last. Enzo GalligioniH-Index: 25
view all 13 authors...
Central nervous system (brain or leptomeningeal) metastases (BLm) are considered rare in castration-resistant prostate cancer (CRPC) patients. Now that docetaxel has become the reference drug for first-line treatment of CRPC, patients whose disease is not controlled by hormonal manipulations may live much longer than before and have higher risk of developing BLm. We retrospectively reviewed the records of all patients with CRPC attending our centres from 2002 to 2010, and identified all of those...
23 CitationsSource
#1Kim N. ChiH-Index: 77
#2Howard I. ScherH-Index: 145
Last. Karim FizaziH-Index: 103
view all 15 authors...
15 Background: AA, a selective androgen biosynthesis inhibitor, blocks the action of CYP17, thereby inhibiting adrenal and intratumoral androgen synthesis. AA has demonstrated improved overall survival (OS) by 4.6 months (mos) vs placebo (HR=0.74) in patients (pts) previously treated with D. Methods: COU-AA-301 is a randomized double-blind study of AA (1 g) + P (5 mg po BID) vs placebo + P administered to mCRPC pts post-D with a primary endpoint of OS. To evaluate the robustness of the primary s...
21 CitationsSource
#1Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 67
#2Elizabeth Ward (ACS: American Cancer Society)H-Index: 86
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 139
view all 4 authors...
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. A total of 1,596,670 new cancer cases an...
3,510 CitationsSource
#1Johann S. de BonoH-Index: 124
Last. Howard I. Scher (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 145
view all 32 authors...
BACKGROUND Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy. METHODS We randomly assigned, in a 2:1 ratio, 1195 patients who had previously received docetaxel to receive 5 mg of prednisone twice daily with either 1000 mg of abirat...
2,979 CitationsSource
#1A. O. SartorH-Index: 7
#2Stephane OudardH-Index: 72
Last. J.S. de BonoH-Index: 58
view all 7 authors...
4525^ Background: Docetaxel is standard first-line chemotherapy for mCRPC. The Phase III TROPIC trial showed that, for patients who progressed during or after docetaxel-based therapy, cabazitaxel plus prednisone (CbzP) improved overall survival (OS) compared with mitoxantrone plus prednisone (MP) (HR 0.70; p < 0.0001) (Lancet 2010; 376:1147–54). We conducted an exploratory analysis of the TROPIC cohort to assess OS from the time of first docetaxel treatment. Methods: Men were randomized to recei...
18 CitationsSource
#1Yu-Yun Shao (NTU: National Taiwan University)H-Index: 24
#2Li-Chun LuH-Index: 13
Last. Chih-Hung Hsu (NTU: National Taiwan University)H-Index: 43
view all 4 authors...
Aim. Brain metastasis was regarded, until recently, as a rare and late-stage event in patients with hepatocellular carcinoma (HCC). With the prolongation of survival in patients with advanced HCC by molecular targeted
25 CitationsSource
#1Johann S. de Bono (ICR: Institute of Cancer Research)H-Index: 124
#2Stéphane OudardH-Index: 6
Last. A. Oliver Sartor (Tulane University)H-Index: 19
view all 13 authors...
Summary Background Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers. We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment. Methods We undertook an open-label randomised phase 3 trial in men with metastatic castration-resistant prostate cancer who had received ...
2,970 CitationsSource
#1Philip W. Kantoff (Harvard University)H-Index: 134
#2Celestia S. Higano (UW: University of Washington)H-Index: 86
Last. Paul F. Schellhammer (EVMS: Eastern Virginia Medical School)H-Index: 73
view all 13 authors...
Background Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. Methods In this double-blind, placebo-controlled, multicenter phase 3 trial, we randomly assigned 512 patients in a 2:1 ratio to receive either sipuleucel-T (341 patients) or placebo (171 patients) administered intravenously every 2 weeks, for a total of three infusions. The primary end point was overall...
4,945 CitationsSource
Cited By15
Newest
#1Niamh Peters (Cork University Hospital)H-Index: 1
#2Mohammed Zeeshan Zeeshan Zemeer (Cork University Hospital)
Last. Richard Martin Bambury (Cork University Hospital)H-Index: 14
view all 4 authors...
A 59-year-old man with a known breast cancer type 1 gene mutation and a 2-year history of metastatic prostate cancer to bone and lymph nodes presented with a sudden onset of thunderclap headache, photophobia and a left sided facial droop. He was being treated at the time with the poly ADP ribose polymerase inhibitor Rucaparib. Of note, 6 weeks prior to this presentation, he had been diagnosed with malignant spinal cord compression at T3-T6, he underwent an emergency decompressive laminectomy and...
Source
#1Rhiannon McBean (Wesley Hospital)H-Index: 7
#2Annaleis Tatkovic (Wesley Hospital)H-Index: 1
Last. David Wong (Wesley Hospital)H-Index: 13
view all 3 authors...
Objectives Prostate cancer metastasizing to the brain is remarkably uncommon, with the incidence never having been described in the modern setting. The objective of this study was to determine the incidence and imaging pattern of intracranial metastasis from prostate cancer in a large cohort of Australian men with prostate cancer. Material and methods Retrospective review was undertaken of imaging reports for all known prostate cancer patients, who underwent an imaging examination inclusive of t...
Source
#1Zarhra Saadatpour (UAB: University of Alabama at Birmingham)
#2Ali Rezaei (UAB: University of Alabama at Birmingham)
Last. Kamran Tavakol (HU: Howard University)H-Index: 5
view all 5 authors...
Despite the high prevalence of prostate cancer, its brain parenchymal metastasis is not common and intracranial hemorrhage due to such a metastasis is even less common. This report presents a challenging case of solitary brain metastasis secondary to prostate cancer that gave rise to intraventricular hemorrhage and acute hydrocephalus mimicking a giant aneurysm. A 77-year-old man with a history of prostate cancer, hypertension, and morbid obesity presented to the emergency room with a severe hea...
Source
#1Suhu Liu (Albert Einstein College of Medicine)
#2Ahmed H Qavi (Albert Einstein College of Medicine)H-Index: 4
Last. Stephen Jesmajian (Albert Einstein College of Medicine)H-Index: 7
view all 5 authors...
Intracranial metastasis from prostate adenocarcinoma is rare. A 70-year-old African American male with a history of prostate adenocarcinoma for the last 14 years, presented to our hospital complain...
Source
#1Hriday P. Bhambhvani (Stanford University)H-Index: 5
#2Monica Granucci (Stanford University)H-Index: 1
Last. Melanie Hayden Gephart (Stanford University)H-Index: 17
view all 5 authors...
Abstract While the majority of brain metastases arise from lung cancer, breast cancer, or melanoma, new treatments and improved prognoses have altered the profile of primary cancers that metastasize to the brain. We sought to determine the proportion of brain metastases from less common primary sites and conduct trend analyses. We reviewed the charts of 3585 patients with brain metastases seen at our institution from 2008 to 2018. We determined the primary site for each of these patients, and th...
1 CitationsSource
Parenchymal brain metastases from prostate cancer are rare and mostly appear in the terminal phase of the disease. Here, we report a case of cystic cerebral metastases in patient with prostate adenocarcinoma. This patient presented with one large parietal polycystic tumor and three other suspicious-looking nodular lesions as shown on magnetic resonance imaging. This is the twelfth reported case of prostatic brain metastasis occurring as a cystic intraparenchymal tumor in the literature.
Source
#1Yohei Shida (Nagasaki University)H-Index: 6
#2Tomoaki Hakariya (Nagasaki University)H-Index: 8
Last. Hideki Sakai (Nagasaki University)H-Index: 24
view all 4 authors...
Brain metastasis from prostate cancer may be becoming more common and may be associated with occurrence of diffuse systemic metastases.
2 CitationsSource
#1Fumio Ishizaki (Niigata University)H-Index: 8
#2Ryo Maruyama (Niigata University)H-Index: 6
Last. Yoshihiko Tomita (Niigata University)H-Index: 27
view all 6 authors...
Abstract We herein report an unusual case of brain metastasis from prostate cancer during androgen deprivation therapy and post-docetaxel and definitive local therapy. The brain metastasis was surgically resected followed by Whole-brain radiation therapy. Postoperatively, his PSA again decreased to an undetectable level and remained undetectable with no evidence of new or recurrent disease.
2 CitationsSource
#1Timothy L. Sita (NU: Northwestern University)H-Index: 4
#2Katarina Petras (NU: Northwestern University)H-Index: 3
Last. Tim J. Kruser (NU: Northwestern University)H-Index: 18
view all 5 authors...
Intracranial metastasis from prostate cancer is rare. As treatment of castration-resistant prostate cancer improves, the incidence of men with intracranial metastasis from prostate cancer is increasing. Radiation therapy for treatment of intracranial metastasis from prostate cancer is systematically reviewed. A comprehensive review examining peer-reviewed, English language articles from 1990 to 2015 was performed on multiple databases, yielding 1274 articles. These articles were reviewed and sel...
5 CitationsSource
: Despite the high rate of prostate cancer, the incidence of penile metastasis originating from prostate cancer is extremely rare, especially in the form of Peyronie’s disease. Moreover, brain metastasis, which is caused by prostate cancer, is not a common phenomenon and occurs mostly in older patients. Herein, we report a case of a middle-aged man with penile and brain metastasis originating from prostate cancer. The patient was presented with signs and symptoms of Peyronie’s disease without a ...
Source